На этой странице перечислены больницы направления «Хирургическая онкология» (включая Thyroid Cancer Treatment) в Дели (NCR), Индия, включая Apollo Hospitals, Medanta - The Medicity, Artemis Hospital, Fortis Memorial Research Institute и другие.
Спросите нас о «Thyroid Cancer Treatment» в Дели (NCR), Индия
Оставьте свои данные — наша команда координации свяжется с вами и расскажет о следующих шагах.
Сравните 35 аккредитованных больниц (Хирургическая онкология) в Дели (NCR), Индия
Рекомендуем🇮🇳 Apollo Hospitals
Больница занимает 1-е место в этом списке по указанному рейтингу (4.9/5, 1240 отзывов).
🇮🇳 Medanta - The Medicity
Больница занимает 2-е место в этом списке по указанному рейтингу (4.9/5, 2150 отзывов).
🇮🇳 Artemis Hospital
Больница занимает 3-е место в этом списке по указанному рейтингу (4.9/5, 64 отзывов).
🇮🇳 Fortis Memorial Research Institute
Больница занимает 4-е место в этом списке по указанному рейтингу (4.8/5, 1100 отзывов).
🇮🇳 Max Super Specialty Hospital
Больница занимает 5-е место в этом списке по указанному рейтингу (4.8/5, 1300 отзывов).
🇮🇳 All India Institute of Medical Sciences (AIIMS)
Больница занимает 6-е место в этом списке по указанному рейтингу (4.7/5, 3500 отзывов).
🇮🇳 CK Birla Hospital
Больница занимает 7-е место в этом списке по указанному рейтингу (4.7/5, 162 отзывов).
🇮🇳 Centre for Sight
Больница занимает 8-е место в этом списке по указанному рейтингу (4.7/5, 181 отзывов).
🇮🇳 Max Super Specialty Hospital, Gurgaon
Больница занимает 9-е место в этом списке по указанному рейтингу (4.6/5, 95 отзывов).
🇮🇳 Max Super Speciality Hospital, Patparganj
Больница занимает 10-е место в этом списке по указанному рейтингу (4.6/5, 97 отзывов).
🇮🇳 Primus Super Speciality Hospital
Больница занимает 11-е место в этом списке по указанному рейтингу (4.6/5, 142 отзывов).
🇮🇳 PSRI Multispeciality Hospital
Больница занимает 12-е место в этом списке по указанному рейтингу (4.6/5, 318 отзывов).
🇮🇳 Fortis Hospital, Shalimar Bagh
Больница занимает 13-е место в этом списке по указанному рейтингу (4.5/5, 68 отзывов).
🇮🇳 Sarvodaya Hospital
Больница занимает 14-е место в этом списке по указанному рейтингу (4.5/5, 74 отзывов).
🇮🇳 Indian Spinal Injuries Center
Больница занимает 15-е место в этом списке по указанному рейтингу (4.5/5, 76 отзывов).
🇮🇳 Max Super Speciality Hospital, Shalimar Bagh
Больница занимает 16-е место в этом списке по указанному рейтингу (4.5/5, 82 отзывов).
🇮🇳 Fortis Hospital, Noida
Больница занимает 17-е место в этом списке по указанному рейтингу (4.5/5, 88 отзывов).
🇮🇳 Venkateshwar Hospital
Больница занимает 18-е место в этом списке по указанному рейтингу (4.5/5, 69 отзывов).
🇮🇳 CK Birla Hospital
Больница занимает 19-е место в этом списке по указанному рейтингу (4.5/5, 72 отзывов).
🇮🇳 Fortis Flt. Lt. Rajan Dhall Hospital
Больница занимает 20-е место в этом списке по указанному рейтингу (4.5/5, 75 отзывов).
🇮🇳 Asian Institute of Medical Sciences
Больница занимает 21-е место в этом списке по указанному рейтингу (4.5/5, 119 отзывов).
🇮🇳 Manipal Hospitals Dwarka
Больница занимает 22-е место в этом списке по указанному рейтингу (4.4/5, 54 отзывов).
🇮🇳 Sir Ganga Ram Hospital
Больница занимает 23-е место в этом списке по указанному рейтингу (4.4/5, 24 отзывов).
🇮🇳 Fortis Escorts Hospital
Больница занимает 24-е место в этом списке по указанному рейтингу (4.4/5, 31 отзывов).
🇮🇳 Marengo Asia Hospitals
Больница занимает 25-е место в этом списке по указанному рейтингу (4.4/5, 54 отзывов).
🇮🇳 Yatharth Super Specialty Hospital
Больница занимает 26-е место в этом списке по указанному рейтингу (4.4/5, 61 отзывов).
🇮🇳 Paras Hospitals
Больница занимает 27-е место в этом списке по указанному рейтингу (4.4/5, 59 отзывов).
🇮🇳 Fortis Hospital Manesar
Больница занимает 28-е место в этом списке по указанному рейтингу (4.4/5, 74 отзывов).
🇮🇳 Marengo Asia Hospitals Gurgaon
Больница занимает 29-е место в этом списке по указанному рейтингу (4.4/5, 103 отзывов).
🇮🇳 Metro Hospital Noida
Больница занимает 30-е место в этом списке по указанному рейтингу (4.4/5, 121 отзывов).
🇮🇳 Sharda Hospital
Больница занимает 31-е место в этом списке по указанному рейтингу (4.4/5, 130 отзывов).
🇮🇳 Fortis Hospital, Greater Noida
Больница занимает 32-е место в этом списке по указанному рейтингу (4.3/5, 28 отзывов).
🇮🇳 Fortis Escorts Hospital Jaipur
Больница занимает 33-е место в этом списке по указанному рейтингу (4.3/5, 132 отзывов).
🇮🇳 Max Super Speciality Hospital, Saket
Больница занимает 34-е место в этом списке по указанному рейтингу (3.8/5, 49 отзывов).
🇮🇳 BLK-Max Super Speciality Hospital
Больница занимает 35-е место в этом списке по указанному рейтингу (3.8/5, 48 отзывов).
Как мы выбираем эти больницы
Больница появляется на этой странице, если направление «Хирургическая онкология» указано среди её специализаций и она находится в Дели (NCR), Индия. Сортировка — по указанному рейтингу (по убыванию), без редакционного рейтинга «лучших».
Как выбрать лучшую больницу для «thyroid cancer treatment» в Дели (NCR), Индия?
Выбор подходящей больницы для «thyroid cancer treatment» — важное решение в вашем пути лечения. Вот на что стоит обратить внимание:
Международная аккредитация
Ищите больницу с международной аккредитацией, например JCI или NABH — см. отметки аккредитации у каждой больницы ниже.
Специализация
Убедитесь, что в больнице есть отделение, специализирующееся на «Хирургическая онкология», а не только общая помощь.
Мощность и опыт
Количество коек и год основания, указанные ниже, отражают масштаб и операционный опыт больницы.
Прозрачность стоимости
Запросите детализированную смету перед поездкой — используйте наш калькулятор стоимости для первичной оценки.
Что нужно знать о процедуре «Thyroid Cancer Treatment»
Thyroid cancer treatment encompasses a spectrum of curative and disease-modifying interventions—including total thyroidectomy, radioactive iodine (RAI) ablation, targeted molecular therapies, and external beam radiotherapy—tailored to histological subtype and disease staging. Overall five-year survival rates exceed 98% for differentiated thyroid cancers (papillary and follicular) when diagnosed at an early or locoregional stage, underscoring the importance of accessing a high-volume multidisciplinary oncology centre. GAF Healthcare connects international patients with JCI- and NABH-accredited hospitals in India and JCI- and DHA-licensed centres in Dubai and Abu Dhabi, providing end-to-end coordination that combines world-class clinical outcomes with transparent, affordable pricing. Hospital Stay: 3–7 days (varies by surgical extent and adjuvant therapy requirement) • Total Stay in Country (Fit-to-Fly): 2–4 weeks (longer if post-surgical RAI therapy is incorporated into the protocol) • Success Rate: 98%+ (differentiated thyroid cancer, early-to-locoregional stage); 70–85% (locally advanced or recurrent disease managed with targeted therapy)
Clinical Overview
Thyroid cancer arises from the follicular epithelial cells or parafollicular C-cells of the thyroid gland and is classified into four principal histological subtypes: papillary thyroid carcinoma (PTC, ~85% of cases), follicular thyroid carcinoma (FTC, ~10%), medullary thyroid carcinoma (MTC, ~3%), and anaplastic thyroid carcinoma (ATC, <2%). PTC and FTC are collectively termed differentiated thyroid cancers (DTC) and carry the most favourable prognosis because they retain iodine-uptake capability, making them amenable to RAI ablation. MTC originates from calcitonin-secreting parafollicular cells and is associated with RET proto-oncogene mutations, both germline (in the context of MEN2A and MEN2B syndromes) and somatic. ATC is the rarest but most aggressive subtype, frequently presenting with rapid cervical mass expansion, tracheal compression, dysphagia, and hoarseness, demanding an urgent multimodal response. Physiologically, thyroid cancer can disrupt the hypothalamic-pituitary-thyroid (HPT) axis, suppress endogenous TSH secretion through tumour bulk, and compromise parathyroid function when tumour involvement or surgical dissection alters calcium homeostasis. Locoregional spread to cervical lymph nodes is common even in low-risk PTC, necessitating rigorous neck ultrasound mapping and sentinel or selective neck dissection planning. Distant metastases—most often to the lungs and bones—occur in approximately 10–15% of DTC patients and define Stage IVB/IVC disease, requiring systemic treatment escalation beyond RAI. The current standard of care is guided by the American Thyroid Association (ATA) 2015 risk-stratification framework and the TNM 8th Edition staging system. Low-risk DTC (intrathyroidal, node-negative) may be managed with thyroid lobectomy alone and active surveillance protocols. Intermediate-to-high-risk DTC mandates total thyroidectomy, central compartment lymph node dissection, and adjuvant RAI at activities determined by post-operative thyroglobulin (Tg) and whole-body scan findings. Persistently elevated Tg or structural recurrence triggers sorafenib (Nexavar) or lenvatinib (Lenvima)—multikinase inhibitors with proven progression-free survival benefit in RAI-refractory DTC. MTC is managed by total thyroidectomy with bilateral central and lateral neck dissection, with vandetanib or cabozantinib reserved for progressive or metastatic disease; BRAF V600E-mutant PTC responds to dabrafenib–trametinib combination therapy. ATC protocols now incorporate BRAF V600E testing upfront, with dabrafenib plus trametinib achieving a disease control rate of approximately 69% in mutation-positive patients, often used as a bridge to surgery or definitive concurrent chemoradiotherapy.
Who is a Candidate?
• Confirmed thyroid nodule(s) with fine-needle aspiration cytology (FNAC) reported as Bethesda Category V (suspicious for malignancy) or VI (malignant) • Histopathologically proven PTC, FTC, Hurthle cell carcinoma, MTC, or ATC on core needle biopsy or post-lobectomy pathology • Patients with compressive symptoms: progressive dysphagia, stridor, voice hoarseness, or superior vena cava syndrome from a large thyroid mass • MEN2 syndrome carriers or RET mutation-positive individuals (germline testing recommended before prophylactic thyroidectomy) • Recurrent or metastatic DTC progressing on or ineligible for RAI therapy, requiring multikinase inhibitor initiation • Structural recurrence detected on neck ultrasound, CT chest/neck with contrast, or 18F-FDG PET-CT Required Diagnostics (pre-treatment work-up): • High-resolution neck ultrasound with nodule mapping (ACR TIRADS or ATA classification) • Fine-needle aspiration cytology (FNAC) with or without BRAF/RAS/RET molecular testing (ThyroSeq v3 or Afirma GSC for indeterminate nodules) • Serum TSH, Free T3, Free T4, Anti-TPO, Anti-Tg antibodies • Serum calcitonin and CEA (mandatory if MTC suspected) • Serum calcium, PTH, and Vitamin D (parathyroid baseline) • CT neck and chest with IV contrast or MRI neck (for locoregional staging) • 18F-FDG PET-CT (recommended for high-risk DTC, MTC, ATC, or suspected distant metastasis) • Laryngoscopy (vocal cord mobility assessment prior to any thyroid surgery) • 24-hour urine metanephrines (to exclude concurrent phaeochromocytoma in MEN2 patients before surgery) • Echocardiography and cardiac clearance for patients aged >60 or with cardiac comorbidities scheduled for general anaesthesia Contraindications / Special Considerations: • Uncontrolled coagulopathy (correct prior to surgery; target INR <1.5) • Active systemic infection requiring resolution before elective surgery • Severe cardiopulmonary disease with ASA Class IV–V risk (requires multidisciplinary optimisation) • Pregnancy (RAI absolutely contraindicated; surgery ideally deferred to second trimester) • Documented hypersensitivity to lenvatinib, sorafenib, or cabozantinib in patients requiring systemic therapy (alternative agent selection required) • Prior high-dose neck irradiation (increases surgical complexity; mandates experienced head-and-neck oncology surgeon)
Treatment Options & Approaches
Thyroid cancer treatment is subtype-specific and stage-dependent. The following modalities are deployed individually or in multimodal combination: 1. SURGICAL APPROACHES Total Thyroidectomy (TT): The cornerstone of treatment for tumours >1 cm, bilateral disease, extrathyroidal extension, or any MTC/ATC. Performed under general anaesthesia via a low cervical collar incision (Kocher incision). Intraoperative neuromonitoring (IONM) of the recurrent laryngeal nerve (RLN) is standard at high-volume centres. Parathyroid identification and autotransplantation are performed to minimise post-operative hypoparathyroidism. Hemithyroidectomy / Thyroid Lobectomy: Appropriate for confirmed low-risk PTC ≤4 cm confined to one lobe without nodal involvement, per ATA 2015 guidelines. Reduces lifelong levothyroxine dependency risk while maintaining curative intent. Central Compartment Neck Dissection (Level VI): Prophylactic central neck dissection is recommended for MTC and high-risk PTC; therapeutic dissection is performed for clinically node-positive disease. Lateral Neck Dissection (Levels II–V): Indicated for biopsy-confirmed lateral compartment nodal metastases; selective rather than radical dissection is preferred to reduce morbidity. Remote Access / Robotic-Assisted Thyroidectomy: Increasingly available at tertiary Indian and UAE centres. Techniques include the Transaxillary Robotic Thyroidectomy (TART), Bilateral Axillo-Breast Approach (BABA), and Transoral Endoscopic Thyroidectomy Vestibular Approach (TOETVA). These eliminate the cervical scar entirely, with equivalent oncological outcomes for appropriately selected patients (tumour ≤2 cm, BMI <30, no prior neck surgery). The da Vinci Surgical System is utilised at multiple JCI-accredited partner hospitals in India (Apollo, Fortis, Manipal) and the UAE (Cleveland Clinic Abu Dhabi, Mediclinic City Hospital Dubai). 2. RADIOACTIVE IODINE (RAI / I-131) THERAPY Post-operative RAI remnant ablation is indicated for intermediate-to-high-risk DTC. The patient undergoes either levothyroxine withdrawal (raising endogenous TSH to >30 mIU/L) or recombinant human TSH (rhTSH, Thyrogen) stimulation to maximise iodine uptake. Administered activities range from 30–150 mCi for remnant ablation to 100–200+ mCi for adjuvant treatment of metastatic disease. A post-therapy whole-body scan at 5–7 days identifies occult metastases. Patients are isolated per radiation safety protocols for 24–72 hours post-administration. 3. TARGETED MOLECULAR THERAPIES (SYSTEMIC) • RAI-Refractory DTC: Lenvatinib (Lenvima, 24 mg/day) is first-line with a median PFS of 18.3 months (SELECT trial). Sorafenib (Nexavar, 400 mg BID) is an alternative. Cabozantinib (Cabometyx) is approved as second-line post-lenvatinib progression (COSMIC-311 trial). • BRAF V600E-Mutant PTC (advanced/ATC): Dabrafenib (150 mg BID) plus trametinib (2 mg/day) — the only FDA-approved regimen for BRAF V600E-mutant ATC, with an overall response rate of 56% and disease control rate of 69% (BRAFi/MEKi combination). • MTC (progressive/metastatic): Vandetanib (Caprelsa, 300 mg/day) or cabozantinib (Cometriq, 140 mg/day) — both RET/VEGFR kinase inhibitors with FDA approval. The selective RET inhibitor selpercatinib (Retevmo) is indicated for RET mutation-positive MTC with superior selectivity and tolerability. • RET Fusion-Positive PTC: Selpercatinib and pralsetinib (Gavreto) — next-generation RET-selective inhibitors with response rates exceeding 60% in RET fusion-positive thyroid cancer. • NTRK Fusion-Positive Thyroid Cancer: Larotrectinib (Vitrakvi) or entrectinib — tumour-agnostic TRK inhibitors. 4. EXTERNAL BEAM RADIOTHERAPY (EBRT) Used for ATC (concurrent with platinum-based chemotherapy, typically weekly paclitaxel or docetaxel), post-operative high-risk DTC with gross residual disease, and for palliative bone or brain metastases. Intensity-modulated radiotherapy (IMRT) and volumetric-modulated arc therapy (VMAT) minimise dose to adjacent critical structures (spinal cord, oesophagus, salivary glands). Stereotactic body radiotherapy (SBRT) is used for oligometastatic disease. 5. ACTIVE SURVEILLANCE (LOW-RISK MICRO-PTC) For incidentally detected papillary microcarcinomas (≤1 cm, no ETE, no nodal disease), active surveillance with serial ultrasound every 6–12 months is an evidence-based alternative to immediate surgery in carefully selected, informed patients — a protocol pioneered at Kuma Hospital (Japan) and adopted by major international guidelines.
Восстановление
PHASE 1 — PRE-ARRIVAL PREPARATION (2–4 weeks before travel) • GAF Healthcare case manager reviews uploaded medical records, biopsy reports, ultrasound images, and prior treatment history. • Multidisciplinary tumour board (endocrine surgeon, nuclear medicine physician, medical oncologist, endocrinologist) at the partner hospital reviews the case and formulates a personalised treatment plan. • Patient receives a detailed cost estimate, treatment protocol summary, and hospital admission confirmation. • E-Medical Visa application (India) or entry visa assistance (UAE) initiated by GAF Healthcare. • Pre-operative laboratory work (CBC, metabolic panel, coagulation, thyroid function, calcitonin, PTH) and any outstanding imaging (PET-CT, CT contrast) arranged on Day 1–2 of arrival. PHASE 2 — ARRIVAL & PRE-OPERATIVE ASSESSMENT (Day 1–3) • Airport pickup by GAF Healthcare ground coordinator. • Day 1: Hotel check-in; orientation briefing. • Day 2: Hospital pre-admission — anaesthesiology consultation, cardiology clearance if required, laryngoscopy (vocal cord baseline), IONM baseline testing. • Day 3: Endocrine surgeon consultation, surgical consent, bowel prep and pre-operative fasting instructions. For patients undergoing RAI therapy only (non-surgical), low-iodine diet initiated 2 weeks before RAI; rhTSH (Thyrogen) injections on Days 1–2. PHASE 3 — SURGICAL PROCEDURE (Day 3 or 4) • Total thyroidectomy ± central/lateral neck dissection performed under general anaesthesia; duration 2–4 hours depending on extent of dissection. • Robotic-assisted (TOETVA or TART) cases: Duration 3–5 hours; surgeon operates via da Vinci console. • Intraoperative recurrent laryngeal nerve monitoring (IONM) maintained throughout. • Parathyroid glands identified; devascularised glands autotransplanted to sternocleidomastoid muscle. • Frozen section analysis available intra-operatively for margin assessment. • Jackson-Pratt drain placed; patient moved to recovery and monitored for airway patency, haematoma, and hypocalcaemia (calcium and PTH checked at 4 hours and 24 hours post-op). PHASE 4 — HOSPITAL RECOVERY (Day 4–7) • Drain removal at 24–48 hours if output <30 mL/day. • Serum calcium and intact PTH monitoring; oral calcium carbonate and calcitriol initiated prophylactically. • Voice assessment by speech therapist on Day 2 post-op. • Levothyroxine suppression therapy initiated (TSH target <0.1 mIU/L for high-risk, 0.1–0.5 for low-risk). • Wound care education; sutures or surgical glue assessed for integrity. • Pathology report reviewed at Day 5–7 with oncologist; RAI scheduling confirmed if indicated. • Discharge on Day 4–7 post-surgery. PHASE 5 — POST-DISCHARGE RECOVERY IN DESTINATION (Week 2–4) • Patient stays at GAF Healthcare partner accommodation near the hospital. • RAI therapy (if planned): Administered Week 3–4 post-surgery after TSH stimulation. Patient isolated for 24–72 hours. Post-therapy whole-body scan performed at Day 5–7 post-RAI. • Follow-up clinic visit at Week 2 (wound check, calcium optimisation, levothyroxine dose titration). • Molecular therapy initiation (lenvatinib, selpercatinib, etc.) reviewed and prescribed if systemic therapy is part of the plan; first cycle tolerance assessed. • Nutritional counselling, iodine restriction guidance, and radiation safety instructions provided. PHASE 6 — FIT TO FLY & REPATRIATION (Week 3–4 post-surgery; Week 5–6 if RAI included) • Radiation safety clearance issued by nuclear medicine physician (mandatory before air travel post-RAI). • Final discharge summary, histopathology report, post-therapy scan images, and medication list prepared in English and, where applicable, the patient's native language. • GAF Healthcare coordinates airport transfer and provides 24-hour teleconsultation access for the first 12 weeks after return home. • Long-term follow-up protocol: Serum thyroglobulin + anti-Tg antibody at 3, 6, and 12 months; neck ultrasound at 6 and 12 months; whole-body scan at 6–12 months if RAI was administered.
Возможные риски
Thyroid cancer surgery and its adjuvant treatments carry a well-characterised but manageable risk profile that patients should discuss openly with their surgeon. Recurrent laryngeal nerve (RLN) injury is the most clinically significant surgical risk, occurring transiently in 5–8% and permanently in 1–2% of total thyroidectomies at high-volume centres; bilateral injury causing airway compromise is rare (<0.5%) but can necessitate tracheostomy. Hypoparathyroidism with resultant hypocalcaemia is the most common post-operative complication (transient in 20–30%, permanent in 1–3%), requiring long-term calcium and active Vitamin D supplementation. Post-operative haematoma with airway compression occurs in 1–2% of cases and requires emergency re-exploration. Wound infection, seroma, and chyle leak (from thoracic duct injury during lateral neck dissection) are less frequent but recognised complications. Radioactive iodine therapy carries risks of salivary gland inflammation (sialadenitis), transient bone marrow suppression at high activities, dry mouth, altered taste, and, in cases of cumulative high-dose RAI exposure, a small but real increased risk of secondary malignancy (notably leukaemia and salivary gland tumours). Lenvatinib and sorafenib are associated with hypertension (requiring antihypertensive initiation in up to 70% of patients), hand-foot skin reaction, fatigue, diarrhoea, and hepatotoxicity; cardiac QTc prolongation is a specific concern with vandetanib for MTC. Selpercatinib and pralsetinib are better tolerated but require monitoring for hypertension, hepatotoxicity, and interstitial lung disease. Dabrafenib–trametinib can cause pyrexia, rash, and secondary skin malignancies. Patients with ATC have a median overall survival of 3–6 months despite aggressive multimodal therapy; BRAF V600E-positive patients treated with targeted therapy have improved but still guarded short-term prognosis. All patients undergoing total thyroidectomy require lifelong levothyroxine therapy with regular dose monitoring to prevent hypothyroidism and maintain appropriate TSH suppression.
Почему GAF Healthcare
GAF Healthcare provides comprehensive non-medical coordination to ensure that international patients experience a seamless, stress-free treatment journey. VISA ASSISTANCE — INDIA: GAF Healthcare's visa team facilitates the Indian e-Medical Visa application, which is granted electronically within 3–5 business days for patients from over 150 eligible countries. Visa support letters on hospital letterhead, medical appointment confirmation, and document checklist guidance are provided as a complimentary service. Companion e-Medical Visas for up to two attendants are coordinated simultaneously. VISA ASSISTANCE — UAE (DUBAI / ABU DHABI): Citizens of over 50 countries enter the UAE visa-free for up to 30–90 days. For patients from countries requiring a visa, GAF Healthcare coordinates a Tourist or Medical Visa on Arrival through its UAE-based partner network, typically processed within 48–72 hours. Extended stay visas for treatment durations exceeding 30 days are arranged proactively. AIRPORT TRANSFERS: Dedicated private vehicle airport pickup and drop-off is arranged for the patient and all accompanying family members, including wheelchair or stretcher transport for mobility-impaired patients. DEDICATED PATIENT COORDINATOR & TRANSLATION: Every patient is assigned a multilingual GAF Healthcare case manager available 7 days a week via WhatsApp, phone, and email. Professional medical interpreters (Arabic, Russian, French, Swahili, Bengali, and other languages) are arranged for all clinical consultations, surgical consent discussions, and discharge briefings — at no additional cost. ACCOMMODATION FOR ATTENDANTS: GAF Healthcare has negotiated preferential rates at partner serviced apartments and guest houses within 1–5 km of all partner hospitals. Options range from budget-friendly guesthouses (~$25–50/night in India; ~$60–120/night in the UAE) to premium hotel suites, allowing attendants to remain close to the patient throughout the hospital stay and recovery period. POST-TREATMENT FOLLOW-UP: Digital medical record management, international courier of pathology slides for second-opinion review, and scheduled telemedicine consultations with the treating oncologist at 4, 8, and 12 weeks post-discharge are included in the GAF Healthcare coordination package.
Частые вопросы о процедуре «Thyroid Cancer Treatment»
What is the cost of thyroid cancer treatment in India vs. UAE?
How long do I need to stay in India or the UAE before I am fit to fly home after thyroid cancer treatment?
What is the success rate of thyroid cancer treatment?
Похожие страницы
Как GAF Healthcare помогает выбрать лучшую больницу для «thyroid cancer treatment» в Дели (NCR), Индия
Найдите лучшие больницы для «thyroid cancer treatment» в Дели (NCR), Индия
На этой странице представлено 35 больниц в Дели (NCR), Индия, чтобы вы могли сравнить аккредитацию и специализации в одном месте.
Поддержка, когда она нужна
Отправьте нам свои медицинские отчёты в WhatsApp или по email — наша медицинская команда изучит их и предложит больницу и план лечения.
Прозрачные, всё включено цены
Мы предоставляем единую детализированную смету, покрывающую расходы больницы и проживание — без скрытых платежей.
Организация визы, поездки и проживания
После выбора больницы мы помогаем оформить визовое приглашение, забронировать проживание рядом с больницей и организовать трансфер.
Хотите узнать примерную стоимость лечения? Используйте наш калькулятор стоимости для персональной оценки.
Частые вопросы о «Thyroid Cancer Treatment» в Дели (NCR), Индия
Сколько больниц направления «Хирургическая онкология» представлено в Дели (NCR), Индия?
Как вы выбираете больницы для списка?
Сколько стоит лечение в Дели (NCR), Индия?
Следующий шаг
Отправьте нам свои медицинские отчёты — наша команда предложит больницу и план лечения для «Thyroid Cancer Treatment» в Дели (NCR), Индия.
Свяжитесь с нами, если заметите неточность на этой странице.